Keeping Pace in Lung Cancer - HER2: Unveiling New Horizons in NSCLC Treatment
Guest: Jacob Sands, MD
\n\n Host: Charu Aggarwal, MD, MPH
\n\n\n \n
We now have an FDA-approved targeted therapy to treat HER2-mutated NSCLC. Drs. Aggarwal and Sands discuss the most current clinical data, including management of adverse events.